COMMUNIQUÉS West-GlobeNewswire

YSS Corp. Announces Receipt of Retail Cannabis Store License in Edmonton
07/08/2019
CALGARY, Alberta, Aug. 07, 2019 (GLOBE NEWSWIRE) -- YSS Corp.™ (the “ Company ” or “ YSS ”) (TSXV: YSS) (WKN: A2PMAX) is pleased to announce receipt of an additional cannabis retail license from the Alberta Gaming, [...]
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership
07/08/2019
Development pipeline and human trials planned for repeat dosing of AAV-based gene therapies to address the unmet medical need for patients with rare and orphan genetic diseases. WATERTOWN, Mass. and RESEARCH TRIANGLE [...]
Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results
07/08/2019
BERKELEY HEIGHTS, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Zomedica Announces TRUFORMA™ Assay Updates and R&D Expansion
07/08/2019
ANN ARBOR, Mich., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced additional development progress [...]
Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights
07/08/2019
-- Phase 3 MAESTRO-NASH Program Continues to Progress -- -- Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D -- -- Madrigal Presentations Selected for the Liver Meeting ® AASLD 2019 [...]
Teleflex Wins New Zealand Innovation Award for UroLift System for Patients with Enlarged Prostate
07/08/2019
Minimally Invasive Treatment Provides Rapid, Durable Symptom Relief Without Compromising Sexual Function* WAYNE, Pa., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the UroLift ® [...]
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development
07/08/2019
ROCKVILLE, Md., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are [...]
KBP BioSciences Signs Memorandum of Understanding with BullFrog AI
07/08/2019
Envisions Using BullFrog AI Innovative Artificial Intelligence Technology to Expand KBP’s Diverse Product Pipeline PRINCETON, N.J. and JINAN, China, Aug. 07, 2019 (GLOBE NEWSWIRE) -- KBP BioSciences USA , a clinical [...]
Jounce Therapeutics Reports Second Quarter 2019 Financial Results
07/08/2019
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with Celgene, received $50.0 million [...]
Cambrex to be Acquired by the Permira Funds for $60.00 per Share in Cash
07/08/2019
EAST RUTHERFORD, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug [...]
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019
07/08/2019
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today [...]
La Fondation de l’Institut de Cardiologie de Montréal s’associe à Roller Marathon Canada dans le cadre du programme Cours pour le Cœur
07/08/2019
MONTRÉAL, 07 août 2019 (GLOBE NEWSWIRE) -- Vous aimeriez combiner envie de bouger et générosité? Cette année, la Fondation de l’Institut de Cardiologie de Montréal est heureuse de pouvoir compter sur le soutien de [...]
Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer
07/08/2019
Study met primary endpoint showing statistically significant improvement in overall response rate for oral paclitaxel and encequidar (Oral Paclitaxel) compared to IV paclitaxel based on intention-to-treat (ITT) analysis [...]
RavenQuest Provides Shareholder Update
07/08/2019
VANCOUVER, British Columbia, Aug. 07, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) , one of Canada’s most innovative cannabis companies, [...]
Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance
07/08/2019
Positive Phase III results of Oral Paclitaxel show statistically significant improvement in overall response rate in metastatic breast cancer Company is preparing two NDA submissions following successful Phase III [...]
EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
07/08/2019
– Company reports total revenue of $7.2 million – – Two commercial product launches in U.S. are underway for DEXYCU ® and YUTIQ ® with 43 sales reps actively targeting uveitis specialists, cataract surgeons and [...]
Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone
07/08/2019
ORION CORPORATION PRESS RELEASE 7 AUGUST 2019 at 10.30 am EEST Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone Sales of Nubeqa® (darolutamide), jointly developed by Orion Corporation [...]
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
07/08/2019
Geneva, Switzerland and Boston, MA – August 7, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]
ObsEva Reports Second Quarter 2019 Financial Results
07/08/2019
Multiple Major Milestones Expected This Year - Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban - Nolasiban MAA submission targeted for year- end 2019 - Q4:19 Phase 3 data for PRIMROSE 2 trial of linzagolix in [...]

Pages